Comparative Pharmacology
Head-to-head clinical analysis: CALOMIST versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALOMIST versus OLOPATADINE HYDROCHLORIDE.
CALOMIST vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calomist (calcium gluconate) provides calcium ions to stabilize cardiac cell membranes, correct hypocalcemia, and antagonize hyperkalemia-induced cardiotoxicity.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
Mist inhalation: 1-2 actuations (100-200 mcg) delivered orally via nebulizer every 6 hours as needed for bronchospasm; maximum 12 actuations per day.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours; prolonged in renal impairment (up to 20 hours in anuria)
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Renal: 90% unchanged; biliary/fecal: 10%
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category C
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer